ReportWire

Tag: breast cancer treatment

  • Actress Olivia Munn reveals breast cancer diagnosis

    Actress Olivia Munn reveals breast cancer diagnosis

    [ad_1]

    CHICAGO — Actress Olivia Munn announced in an Instagram post Wednesday morning that she has been diagnosed with breast cancer.

    “I hope by sharing this it will help others find comfort, inspiration and support on their own journey,” she said.

    Actress Olivia Munn announced in an Instagram post Wednesday morning that she has been diagnosed with breast cancer.

    She said she and her sister did genetic testing in an effort to be proactive about her health. Both tested negative for 90 different cancer genes.

    SEE MORE: John Mulaney, Oliva Munn share photo of their new baby

    She also had a normal mammogram, but was diagnosed with Luminal B breast cancer in both breasts in 2023. The cancer is aggressive and fast-moving, she said.

    Munn said her doctor decided to calculate her Breast Cancer Risk Assessment Score, which led to an MRI, ultrasound, biopsy and eventually double mastectomy.

    She said in the past 10 months, she’s had four surgeries, and tended to let people see her when she had energy.

    “I’ve kept the diagnosis and the worry and the recovery and the pain medicine and the paper gowns private. I needed to catch my breath and get through some of the hardest parts before sharing,” she said. “I’m lucky. We caught it with enough time that I had options.”

    Munn appeared on the Oscars red carpet Sunday with John Mulaney.

    The two have a son together.

    This is a developing story; check back for updates.

    Copyright © 2024 WLS-TV. All Rights Reserved.

    [ad_2]

    WLS

    Source link

  • Pregnancy After Breast Cancer Is Safe, Landmark Study Says

    Pregnancy After Breast Cancer Is Safe, Landmark Study Says

    [ad_1]

    Jan. 5, 2023 – Planning to have a child is a life-changing decision. For women who have survived breast cancer, the consideration is even more complex. 

    For a long time, there wasn’t definitive research on how pregnancy impacted the likelihood of whether their cancer would return. But initial results from a new study show women who paused protective post-cancer therapies to get pregnant had no increased risk of their cancer coming back. Nearly 3 in 4 women in the study got pregnant, and 64% had a live birth. 

    One of those “babies after breast cancer” was Ronin Andrade, who turns 1 on Jan. 6. His mother, Shayla Johnson, of Assonet, MA, plans to bake him an Instagram-worthy cake. She participated in the research trial.

    “As a woman, I felt like I’ve lost my breasts, I’ve lost my hair, I’ve lost my figure, and losing the ability to have a child would have crushed me. But that didn’t end up being the case, and 9 pounds, 11 ounces later I have one,” said Johnson, 40, who was diagnosed at age 34 and also carries a dangerous genetic mutation associated with breast cancer known as BRCA2.

    One of the most protective treatments to prevent breast cancer from coming back is called “endocrine therapy,” which involves taking certain medications to help prevent the recurrence of cancer cells that feed on hormones such as estrogen or progesterone. The recommended duration of endocrine therapy is 5 to 10 years.

    The study that Johnson participated in, called the POSITIVE Trial, followed 518 women age 42 or younger who paused their endocrine therapy for approximately 2 years while trying to get pregnant. The study enrolled women with what is known as early-stage breast cancer (up to stage III), which hasn’t spread beyond the breast or nearby lymph nodes. The women completed at least 18 months of endocrine therapy before pausing to try to get pregnant.

    Among those in the study, the breast cancer recurrence rate was 8.9% within an average follow-up period of about 3.5 years. That rate was similar to the 9% average recurrence rate within 3 years established by previous research. The new POSITIVE Trial results were presented in December at the San Antonio Breast Cancer Symposium.

    “These data from the POSITIVE Trial apply to women with early-stage breast cancer which is hormone sensitive who want to have a pregnancy and who want to interrupt endocrine therapy in order to have a pregnancy,” says lead researcher Ann Partridge, MD, MPH, vice chair of medical oncology at Dana-Farber Cancer Institute. “It doesn’t appear that pregnancy … or taking an endocrine therapy break confer a worse prognosis.”

    Is Pregnancy Less Likely After Breast Cancer? 

    Most breast cancer cases occur in middle aged or older women, but 5% of women age 40 and younger are diagnosed with the disease annually. The new research results are important because young women are increasingly delaying childbearing until their 30s. Breast cancer risk increases with age, so more women are facing the disease prior to having children or completing their families.

    “The other important thing to note is that as people get older, it’s harder to get pregnant,” Partridge says. 

    So a woman may be diagnosed in her early 30s, spend a year getting active treatment such as a mastectomy, chemotherapy, and radiation, and then be advised to take 5 to 10 years of endocrine therapy, essentially taking up most of her remaining years of fertility.

    In addition to examining the safety of pausing endocrine therapy, the POSITIVE Trial results offered an important new area of analysis that many breast cancer survivors fretted about: the likelihood of getting pregnant. 

    Previous research shows that chemotherapy can negatively impact fertility, while endocrine therapy is considered safe — although women should not take it while seeking to get pregnant, says oncologist and  Matteo Lambertini, MD, PhD, of the University of Genova, Italy, who is an expert in pregnancy after breast cancer.

    “Half of newly diagnosed women say they are concerned about fertility,” Lambertini says. 

    Researchers said POSITIVE Trial participants got pregnant or gave birth at rates the same as or higher than the general population.

    Among the 74% of participants who got pregnant, 86% had a live birth. Some women did spend longer than the recommended 2 years paused from endocrine therapy, according to data presented at the symposium. Among participants, 75% had no prior births, 94% had stage I or II breast cancer, and 62% received chemotherapy.

    Partridge says 43% of women in the study used some form of assistive reproductive technology (ART), such as in vitro fertilization (IVF), but researchers haven’t yet analyzed what proportion of pregnancies were a result of ART.

    “Sometimes people are using ART not because they are infertile, but because they want to avoid a BRCA mutation or they want to get pregnant faster using embryos,” Partridge says. “Especially for a BRCA mutation carrier, they may want to implant an embryo that has no mutation … We have to dive much deeper into those data. There’s lots of nuance.”

    Partridge and Lambertini caution that longer follow-up among the study participants is needed to fully understand any longer-term risks pregnancy or pausing endocrine therapy may have.

    Fertility to the Forefront 

    Caitlin Baltera, 34, of Colorado Springs, CO, is 1 year in to her 2 years of paused endocrine therapy while trying to get pregnant. 

    “It’s definitely hard being told that you have 2 years,” says Baltera, who was diagnosed with stage I breast cancer at age 30. “Of course, everyone tells you when you’re trying to conceive, ‘Be calm. Don’t worry.’ And I’m like, I only have 2 years.”

    “Most people don’t usually have a cutoff point where if you continue to try you may be putting yourself in danger,” she says.

    Baltera, who was starting a new relationship when she was diagnosed and is now married, has spent nearly $30,000 on fertility treatments, some of that toward pre-paid IVF cycles. She says her insurance did an excellent job of covering the costs of her cancer treatments, which included chemotherapy that is known to affect fertility.

    Some breast cancer survivors are starting to call for changes in how fertility is covered, similar to a previous movement that surrounded coverage of breast reconstruction. U.S. law now requires that most group insurance plans cover the cost of breast reconstructive surgery.

    “It has made me angry many times to think it’s covered if you want to have a reconstruction or whatever your option is, whether it’s fat grafting or implants, that’s all covered. But with fertility, it’s different,” Baltera says. “Many of us, we are medically infertile. And if you’re going to be proud of offering reconstruction, there’s this other side effect that seems to not be mentioned.”

    Caragh Logan, of London, agrees that there needs to be more focus on the impacts of breast cancer on fertility. She was among the many women in a Babies After Breast Cancer Facebook group eagerly awaiting the POSITIVE Trial results.

    “There are so many young women going through breast cancer every year having to make really hard decisions, and we need some direction, we need some clarity,” says Logan, who is 37. “If this were men, and the risk were men’s, I think they would have looked at things like this earlier.”

    Logan was diagnosed with breast cancer in 2017 and had a recurrence that spread to her spine in 2020. But after treatment she has had what’s called no evidence of disease. She asked her oncologist if the POSITIVE Trial results would apply to her situation, since her cancer had advanced past the trial parameters but then responded to treatment.

    “My previous oncologist said he’d be happy for me to try when I got to my 5 years on tamoxifen [a hormone therapy for breast cancer] in October 2023 if I were willing to accept the risk,” Logan says. “But he recently retired and the new oncologist is much more cautious.”

    She had her eggs harvested prior to her first treatment and will consider surrogacy if she doesn’t move forward with trying to carry a pregnancy. But that’s something she says she will evaluate when her 5 years of endocrine therapy are complete.

    Lambertini says breast cancer experts are planning next year to formally start discussing the matter of pregnancy for women with breast cancer that was more advanced than that studied in the POSITIVE Trial. Because treatments have become so successful, women are living longer than ever before with a stage IV (or metastatic) breast cancer diagnosis. One of Lambertini’s stage IV patients has had a complete response to treatment for 6 years and wants to have a child.

    “Right now we cannot say it is safe at all because we don’t have any data,” he says. “We may potentially cure patients with advanced disease. She is 39. So she is still completely on time to have a pregnancy. But it’s a data-free zone. It’s very difficult for us, as well, to counsel our patients on this.”

    Also forthcoming are results of a large international study looking at the safety of pregnancy among women who carry the BRCA genetic mutation, which is linked with increased cancer risks. Those results will be published in the fall of 2023, Lambertini says. 

    [ad_2]

    Source link

  • Antibody Drug Boosts Survival for Type of Advanced Breast Cancer

    Antibody Drug Boosts Survival for Type of Advanced Breast Cancer

    [ad_1]

    By Dennis Thompson 

    HealthDay Reporter

    THURSDAY, Dec. 8, 2022 (HealthDay News) — A relatively new drug is boosting survival rates for women with a specific type of advanced breast cancer who haven’t responded to other treatments, according to a pair of clinical trials.
     

    The targeted antibody drug — trastuzumab deruxtecan (T-DXd, sold under the brand name Enhertu) — dramatically outperformed an older antibody drug in one trial, quadrupling the number of months women survived without their cancer progressing.

    T-DXd also outperformed standard chemotherapy in another clinical trial, more than doubling the number of months of progression-free survival and reducing the risk of death by 34%.

    T-DXd is aimed at helping patients who have HER2-positive breast cancers.

    HER2 is a protein that promotes growth of breast cancer cells. About 20% of patients have tumors with higher levels of HER2.

    Results from both clinical trials were reported Wednesday at the San Antonio Breast Cancer Symposium.

    “We have a drug that is very effective and seems to be working, at least in good part, by a targeting mechanism against HER2,” said Dr. Carlos Arteaga, chair of comprehensive oncology for the Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, in Dallas.

    Arteaga, co-director of the symposium, led a news briefing announcing the results of the two trials.

    T-DXd delivers a one-two punch to breast cancer cells by combining an antibody called trastuzumab with a chemotherapy drug called deruxtecan.

    The antibody part of T-DXd binds with HER2 receptors on the breast cancer tumor, blocking the ability of the protein to promote cancer growth. This binding also serves to steer cancer-killing deruxtecan directly into tumor cells.

    The U.S. Food and Drug Administration approved T-DXd in 2019 as a follow-up therapy for patients whose breast cancer had continued to spread despite prior treatments with other cancer drugs.

    Ongoing clinical trials have been aimed at figuring out how effective T-DXd is compared to other drugs, and when it should be implemented in treating advanced HER2-positive breast cancers.

    One clinical trial compared T-DXd as a follow-up treatment against trastuzumab emtansine (T-DM1), an earlier antibody drug that combined trastuzumab with a different chemo agent.

    The 524 patients in that trial randomly were treated with one of the two drugs, after they had stopped responding to initial therapies.

    About one in five patients (21%) wound up cancer-free following treatment with T-DXd, compared with nearly 10% of those receiving T-DM1, the researchers reported.

    Further, more than 78% had some clinical response to T-DXd, compared with 35% responding to T-DM1.

    Patients treated with T-DXd had nearly 29 months of progression-free survival on average, about four times the 7 months seen in patients receiving T-DM1, which is sold under the brand name Kadcyla.

    Patients who received T-DXd also had a 36% lower overall risk of death than patients treated with T-DM1, said clinical trial researcher Dr. Sara Hurvitz, a professor with the University of California, Los Angeles, Geffen School of Medicine and Jonsson Comprehensive Cancer Center.

    “These updated results do demonstrate remarkable (overall survival) and (progression-free survival) benefits, solidly placing T-DXd as the standard of care,” Hurvitz said in a news briefing.

    The other clinical trial compared T-DXd to standard chemotherapy as a follow-up treatment.

    The trial involved more than 600 patients whose breast cancers had continued to grow following T-DM1 treatment. About two-thirds received T-DXd, and the rest received chemo.

    Breast cancer patients were 64% less likely to die or have their cancer continue to spread following treatment with T-DXd compared to chemotherapy, the researchers found

    Average progression-free survival was nearly 18 months with T-DXd, more than twice the 7 months achieved with chemotherapy.

    Overall survival also was significantly longer, 39 months on average for T-DXd patients compared to 26 months with chemo.

    About 14% of patients wound up cancer-free following T-DXd treatment in this trial, compared to 5% for chemo.

    The trial “confirms the favorable benefit/risk ratio of T-DXd in patients with advanced HER2 positive breast cancer,” said clinical trial researcher Dr. Ian Krop, chief clinical research officer at the Yale Cancer Center in New Haven, Conn.

    In both trials, the most concerning side effect of T-DXd was damage to the lung, either through inflammation or scarring of lung tissue.

    About 6% suffered lung inflammation and 3% lung scarring in Krop’s trial, while about 15% suffered lung inflammation or scarring in Hurvitz’s trial.

    It’s not yet clear why the drug would cause these side effects in the lungs, Hurvitz said, noting that it doesn’t seem to be driven by the cancer spreading into the lungs.

    “We should, as clinicians, continue to follow CT scans of the lungs closely in our patients being treated with T-DXd, because this is an event that can occur even up to a year or longer of a patient being on therapy,” Hurvitz said.

    Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.

    More information

    The American Cancer Society has more about HER2-positive breast cancer.

     

    SOURCES: Carlos Arteaga, MD, chair, comprehensive oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas; Sara Hurvitz, MD, professor, University of California, Los Angeles, David Geffen School of Medicine and Jonsson Comprehensive Cancer Center; Ian Krop, MD, PhD, chief clinical research officer, Yale Cancer Center, New Haven, Conn.; presentation, San Antonio Breast Cancer Symposium, Dec. 6 to 10, 2022

    [ad_2]

    Source link